PRA Health Sciences (NASDAQ:PRAH) Downgraded by BidaskClub

BidaskClub downgraded shares of PRA Health Sciences (NASDAQ:PRAH) from a strong-buy rating to a buy rating in a research report released on Friday, January 5th.

Several other research firms also recently weighed in on PRAH. Zacks Investment Research downgraded shares of PRA Health Sciences from a buy rating to a hold rating in a research report on Tuesday, January 2nd. Mitsubishi UFJ Financial Group assumed coverage on shares of PRA Health Sciences in a research report on Friday, December 15th. They issued an overweight rating and a $102.00 price target on the stock. Barclays began coverage on shares of PRA Health Sciences in a research report on Monday, December 11th. They issued an overweight rating and a $94.00 price target on the stock. Mizuho set a $87.00 price objective on shares of PRA Health Sciences and gave the company a buy rating in a research report on Friday, December 1st. Finally, SunTrust Banks restated a buy rating and set a $101.00 price objective on shares of PRA Health Sciences in a research report on Friday, October 27th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. PRA Health Sciences has a consensus rating of Buy and a consensus target price of $92.00.

PRA Health Sciences (NASDAQ:PRAH) traded down $1.28 during trading hours on Friday, hitting $90.06. 353,100 shares of the stock were exchanged, compared to its average volume of 443,678. PRA Health Sciences has a 1 year low of $54.08 and a 1 year high of $92.84. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $5,707.08, a PE ratio of 50.31, a price-to-earnings-growth ratio of 1.26 and a beta of 0.41.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. The firm had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.64 earnings per share. sell-side analysts forecast that PRA Health Sciences will post 3.2 EPS for the current year.

In related news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David W. Dockhorn sold 72,850 shares of PRA Health Sciences stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $90.83, for a total transaction of $6,616,965.50. Following the transaction, the executive vice president now directly owns 72,850 shares of the company’s stock, valued at $6,616,965.50. The disclosure for this sale can be found here. Insiders sold a total of 150,815 shares of company stock valued at $13,642,620 over the last three months. Corporate insiders own 2.10% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in PRA Health Sciences by 12.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after buying an additional 160 shares in the last quarter. Carroll Financial Associates Inc. lifted its holdings in PRA Health Sciences by 127.4% during the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after buying an additional 790 shares in the last quarter. Comerica Bank bought a new stake in PRA Health Sciences during the 3rd quarter valued at about $214,000. Trustmark National Bank Trust Department bought a new stake in PRA Health Sciences during the 2nd quarter valued at about $225,000. Finally, Vident Investment Advisory LLC bought a new stake in shares of PRA Health Sciences in the 3rd quarter valued at about $247,000. Institutional investors own 98.23% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “PRA Health Sciences (NASDAQ:PRAH) Downgraded by BidaskClub” was originally reported by BBNS and is owned by of BBNS. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/pra-health-sciences-prah-rating-lowered-to-buy-at-bidaskclub/1820752.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.